Heart valve disease is a growing global health challenge, affecting over 30 million people worldwide. As the global population ages, the incidence of this condition is expected to rise, leading to a growing demand for effective treatment options. Traditionally, heart valve disease was treated with open-heart surgery, a procedure that comes with significant risks, especially for older patients or those with comorbidities.
However, the advent of transcatheter valve repair and replacement procedures has revolutionized the treatment landscape. These minimally invasive procedures offer patients a safe and effective alternative to traditional surgery, with faster recovery, fewer complications, and shorter hospital stays. Since the approval of transcatheter aortic valve replacement/implantation (TAVR/TAVI) in 2011, this innovative approach has expanded to include a wider range of heart valves.
As the technology continues to evolve, the market for transcatheter valve repair and replacement is seeing significant growth. This article explores the factors driving this rise, the future outlook for transcatheter valve repair and replacement, and the continued role of traditional surgical approaches in treating valve disease.
Transcatheter valve repair and replacement have rapidly become cornerstones in the treatment of heart valve disease. These procedures involve inserting a catheter through a small incision, typically in the groin or chest, and threading it to the heart to deliver a new valve or repair an existing one. The procedure is minimally invasive, meaning patients can often return to their normal activities much faster than with traditional surgery.
The first major breakthrough came with TAVR, which was approved for treating aortic valve disease. Since then, the technology has expanded to include other valves, such as the tricuspid, pulmonary, and mitral valves. In 2024, Edwards Lifesciences received FDA approval for the EVOQUE Valve Replacement System, the first device to treat tricuspid regurgitation (TR) via a transcatheter approach.
This approval marks a significant milestone in the treatment of valve disease, highlighting the potential of transcatheter valve repair and replacement to revolutionize structural heart care. The shift to minimally invasive options is not only improving patient outcomes but also expanding the number of patients eligible for treatment.
The transcatheter valve repair and replacement market is experiencing explosive growth, driven by increasing adoption rates and significant technological advances. According to LSI’s Market Intelligence team, approximately 1.1 million heart valve procedures are expected to be performed globally in the coming years. Transcatheter valve repair and replacement procedures are projected to account for nearly 41% of these.
By 2030, transcatheter valve repair and replacement are expected to make up more than half of all structural heart procedures, marking a significant shift from traditional surgical treatments. Despite this rapid rise, surgical valve replacements and repairs continue to grow as well, with a compound annual growth rate (CAGR) of 4.4% projected through 2028.
While transcatheter valve repair and replacement offer significant benefits, such as shorter recovery times and fewer complications, there are still situations where traditional surgery remains the preferred option. For patients who require long-term durability or have more complex conditions, surgical valve replacement offers a higher level of device longevity and stability, making it the more suitable choice in some instances.
Both surgical and transcatheter valve repair and replacement methods are critical to providing personalized care for patients with valve disease. The continued innovation in both areas ensures that heart valve disease treatment remains a rapidly evolving field.
The future of transcatheter valve repair and replacement looks incredibly promising, with continued technological advancements expected to expand its role in structural heart care. As the field matures, transcatheter valve repair and replacement procedures are likely to become the first-line treatment for a growing number of patients, offering faster recovery and fewer complications than traditional surgery.
At the same time, the importance of traditional valve repair and replacement surgeries cannot be overlooked. These procedures remain essential for patients with specific needs, including those who require long-term durability or have complex medical conditions. The future of valve disease treatment will rely on a balance of both approaches to ensure that all patients receive the care that best suits their individual needs.
The market for transcatheter valve repair and replacement is rapidly growing, driven by innovation, increasing patient demand, and expanding indications for various valve diseases. With the potential to improve patient outcomes through faster recovery and fewer complications, transcatheter valve repair and replacement are poised to become a dominant force in the treatment of heart valve disease.
As the technology continues to evolve, it will be essential for healthcare providers to maintain a flexible approach to treatment, incorporating both transcatheter valve repair and replacement and traditional surgery to meet the diverse needs of patients. The future of heart valve disease treatment is bright, with transcatheter valve repair and replacement playing a pivotal role in shaping the next generation of structural heart care.
Gain access to the latest data and insights driving the medtech industry. Explore our Global Procedure Volumes Database to stay informed on key market trends and make data-driven decisions.
Looking for customized solutions? Reach out to our team of experts to discover how LSI’s Market Intelligence services can help you navigate industry changes and stay ahead of the competition.
Schedule an exploratory call
Request Info© 2025 Life Science Intelligence, Inc., All Rights Reserved. | Privacy Policy
